Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.85 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.59 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.59 |
| ▸ | NOS2 | P35228 | 9/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | APEX1 | P27695 | 1/20 | 0.85 |
| ▸ | NOS1 | P29475 | 9/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | NOS3 | P29474 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | DDAH1 | O94760 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25365246 | 1.00 | NOS2 (0.85) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL21802133 | 0.98 | NOS2 (0.89) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL29401543 | 0.98 | NOS2 (0.89) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL43288 | 0.98 | NOS2 (0.89) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL27888576 | 0.96 | NOS2 (0.85) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL29361849 | 0.94 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30074239 | 0.94 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL43261 | 0.92 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30631154 | 0.92 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288993 | 0.92 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240009284-A1 | METHOD AND COMPOSITION FOR TREATING ARGINASE 1 DEFICIENCY | AERASE, INC. | 2024-01-11 | — | — | US | disclosed |
| US-11717562-B2 | Method and composition for treating arginase 1 deficiency | AERASE, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-111787941-A | Methods and compositions for treating arginase 1deficiency | 艾瑞思有限公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-3720476-A1 | METHOD AND COMPOSITION FOR TREATING ARGINASE 1 DEFICIENCY | AERase, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-102675156-B | Preparation method of L-homoarginine hydrochloride | UNIV HENAN SCIENCE & TECH | 2013-11-27 | — | — | CN | disclosed |
| CN-102675156-A | Preparation method of L-homoarginine hydrochloride | UNIV HENAN SCIENCE & TECH | 2012-09-19 | — | — | CN | disclosed |
| CN-1724514-B | Preparation method of L-homoarginine hydrochloride | SHANGHAI YIFURUI IND CO LTD | 2010-06-09 | — | — | CN | disclosed |
| CN-1724514-A | Preparation method of L-homoarginine hydrochloride | SHANGHAI YIFURUI IND CO LTD (CN) | 2006-01-25 | — | — | CN | disclosed |
| EP-0625044-B1 | COMPOSITIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLITES OF OPIOID ANALGESICS | DANBIOSYST UK (GB) | 1998-10-07 | — | — | EP | disclosed |
| US-5629011-A | ABSORPTION PROMOTERS FOR DERIVATIVES OF OPIOID ANALGESICS | DANBIOSYST UK LIMITED (GB) | 1997-05-13 | — | — | US | disclosed |
| EP-0625044-A1 | COMPOSITIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLITES OF OPIOID ANALGESICS | DANBIOSYST UK LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015737-A1 | COMPOSITIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLITES OF OPIOID ANALGESICS | DANBIOSYST UK LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |